請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57110
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄧哲明(Che-Ming Teng),潘秀玲(Shiow-Lin Pan) | |
dc.contributor.author | Li-Ting Wang | en |
dc.contributor.author | 王俐婷 | zh_TW |
dc.date.accessioned | 2021-06-16T06:35:11Z | - |
dc.date.available | 2014-10-21 | |
dc.date.copyright | 2014-10-21 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-01 | |
dc.identifier.citation | Aghdassi, A., M. Sendler, A. Guenther, J. Mayerle, C. O. Behn, C. D. Heidecke, H. Friess, M. Buchler, M. Evert, M. M. Lerch and F. U. Weiss (2012). 'Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.' Gut 61(3): 439-448.
Basu, A. and D. Pal (2010). 'Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta in cell survival and cell death.' ScientificWorldJournal 10: 2272-2284. Bolden, J. E., M. J. Peart and R. W. Johnstone (2006). 'Anticancer activities of histone deacetylase inhibitors.' Nat Rev Drug Discov 5(9): 769-784. Bray, F., J. S. Ren, E. Masuyer and J. Ferlay (2013). 'Global estimates of cancer prevalence for 27 sites in the adult population in 2008.' Int J Cancer 132(5): 1133-1145. Castedo, M., J. L. Perfettini, T. Roumier, K. Andreau, R. Medema and G. Kroemer (2004). 'Cell death by mitotic catastrophe: a molecular definition.' Oncogene 23(16): 2825-2837. Cerda, S. R., M. Bissonnette, B. Scaglione-Sewell, M. R. Lyons, S. Khare, R. Mustafi and T. A. Brasitus (2001). 'PKC-delta inhibits anchorage-dependent and -independent growth, enhances differentiation, and increases apoptosis in CaCo-2 cells.' Gastroenterology 120(7): 1700-1712. Chambard, J. C., R. Lefloch, J. Pouyssegur and P. Lenormand (2007). 'ERK implication in cell cycle regulation.' Biochimica et Biophysica Acta 1773(8): 1299-1310. Chang, L. and M. Karin (2001). 'Mammalian MAP kinase signalling cascades.' Nature 410(6824): 37-40. Chipuk, J. E. and D. R. Green (2005). 'Do inducers of apoptosis trigger caspase-independent cell death?' Nat Rev Mol Cell Biol 6(3): 268-275. Cohen, E., I. Ophir and Y. B. Shaul (1999). 'Induced differentiation in HT29, a human colon adenocarcinoma cell line.' J Cell Sci 112 ( Pt 16): 2657-2666. Comalada, M., E. Bailon, O. de Haro, F. Lara-Villoslada, J. Xaus, A. Zarzuelo and J. Galvez (2006). 'The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype.' J Cancer Res Clin Oncol 132(8): 487-497. Creamer, B., R. G. Shorter and J. Bamforth (1961). 'The turnover and shedding of epithelial cells. I. The turnover in the gastro-intestinal tract.' Gut 2: 110-118. Danial, N. N. and S. J. Korsmeyer (2004). 'Cell death: critical control points.' Cell 116(2): 205-219. Dhanasekaran, D. N. and E. P. Reddy (2008). 'JNK signaling in apoptosis.' Oncogene 27(48): 6245-6251. Ding, Q., Q. Wang and B. M. Evers (2001). 'Alterations of MAPK activities associated with intestinal cell differentiation.' Biochem Biophys Res Commun 284(2): 282-288. Dong, Y., Q. Shi, Y. N. Liu, X. Wang, K. F. Bastow and K. H. Lee (2009). 'Antitumor agents. 266. Design, synthesis, and biological evaluation of novel 2-(furan-2-yl)naphthalen-1-ol derivatives as potent and selective antibreast cancer agents.' Journal of Medicinal Chemistry 52(11): 3586-3590. Eymin, B., P. Claverie, C. Salon, C. Brambilla, E. Brambilla and S. Gazzeri (2006). 'p14ARF triggers G2 arrest through ERK-mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation.' Cell Cycle 5(7): 759-765. Ferlay, J., I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. Parkin, D. Forman and F. Bray (2013). 'GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet].' Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Gajate, C., I. Barasoain, J. M. Andreu and F. Mollinedo (2000). 'Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1 -one: protection by Bcl-2 and Bcl-X(L) and cell cycle arrest.' Cancer Research 60(10): 2651-2659. Gascoigne, K. E. and S. S. Taylor (2008). 'Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs.' Cancer Cell 14(2): 111-122. Gascoigne, K. E. and S. S. Taylor (2009). 'How do anti-mitotic drugs kill cancer cells?' Journal of Cell Science 122(Pt 15): 2579-2585. Gentile, A., L. Trusolino and P. M. Comoglio (2008). 'The Met tyrosine kinase receptor in development and cancer.' Cancer Metastasis Rev 27(1): 85-94. Gherardi, E., W. Birchmeier, C. Birchmeier and G. Vande Woude (2012). 'Targeting MET in cancer: rationale and progress.' Nat Rev Cancer 12(2): 89-103. Gloor, F. J. (1986). 'The adenoma-carcinoma sequence of the colon and rectum.' Sozial- und Praventivmedizin 31(2): 74-75. Gottesfeld, J. M. and D. J. Forbes (1997). 'Mitotic repression of the transcriptional machinery.' Trends in Biochemical Sciences 22(6): 197-202. Griner, E. M. and M. G. Kazanietz (2007). 'Protein kinase C and other diacylglycerol effectors in cancer.' Nat Rev Cancer 7(4): 281-294. Gundersen, G. G. and T. A. Cook (1999). 'Microtubules and signal transduction.' Current Opinion in Cell Biology 11(1): 81-94. Hinnebusch, B. F., S. Meng, J. T. Wu, S. Y. Archer and R. A. Hodin (2002). 'The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation.' Journal of Nutrition 132(5): 1012-1017. Hodin, R. A., S. Meng, S. Archer and R. Tang (1996). 'Cellular growth state differentially regulates enterocyte gene expression in butyrate-treated HT-29 cells.' Cell Growth Differ 7(5): 647-653. Hormanseder, E., T. Tischer and T. U. Mayer (2013). 'Modulation of cell cycle control during oocyte-to-embryo transitions.' EMBO J 32(16): 2191-2203. Hu, Y., M. Bally, W. H. Dragowska and L. Mayer (2003). 'Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.' Mol Cancer Ther 2(7): 641-649. Humphries, A. and N. A. Wright (2008). 'Colonic crypt organization and tumorigenesis.' Nat Rev Cancer 8(6): 415-424. Johnson, G. L. and R. Lapadat (2002). 'Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.' Science 298(5600): 1911-1912. Jordan, M. A., D. Thrower and L. Wilson (1991). 'Mechanism of inhibition of cell proliferation by Vinca alkaloids.' Cancer Research 51(8): 2212-2222. Jordan, M. A. and L. Wilson (2004). 'Microtubules as a target for anticancer drugs.' Nat Rev Cancer 4(4): 253-265. Kerr, D. (2003). 'Clinical development of gene therapy for colorectal cancer.' Nat Rev Cancer 3(8): 615-622. Khavari, D. A., G. L. Sen and J. L. Rinn (2010). 'DNA methylation and epigenetic control of cellular differentiation.' Cell Cycle 9(19): 3880-3883. Kilner, J., B. M. Corfe and S. J. Wilkinson (2011). 'Modelling the microtubule: towards a better understanding of short-chain fatty acid molecular pharmacology.' Mol Biosyst 7(4): 975-983. Kim, N. H., S. N. Kim and Y. K. Kim (2011). 'Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion.' Biochem Biophys Res Commun 404(4): 915-921. Kim, Y. H., J. H. Lim, T. J. Lee, J. W. Park and T. K. Kwon (2007). 'Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C-delta (PKC-delta) signal pathway.' J Cell Biochem 101(4): 987-995. Koivunen, J., V. Aaltonen and J. Peltonen (2006). 'Protein kinase C (PKC) family in cancer progression.' Cancer Lett 235(1): 1-10. Kolomeichuk, S. N., D. T. Terrano, C. S. Lyle, K. Sabapathy and T. C. Chambers (2008). 'Distinct signaling pathways of microtubule inhibitors--vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively.' FEBS J 275(8): 1889-1899. Krishna, M. and H. Narang (2008). 'The complexity of mitogen-activated protein kinases (MAPKs) made simple.' Cellular and Molecular Life Sciences 65(22): 3525-3544. Launay, S., O. Hermine, M. Fontenay, G. Kroemer, E. Solary and C. Garrido (2005). 'Vital functions for lethal caspases.' Oncogene 24(33): 5137-5148. Leblond, C. P. and B. E. Walker (1956). 'Renewal of cell populations.' Physiological Reviews 36(2): 255-276. Lenormand, P., J. M. Brondello, A. Brunet and J. Pouyssegur (1998). 'Growth factor-induced p42/p44 MAPK nuclear translocation and retention requires both MAPK activation and neosynthesis of nuclear anchoring proteins.' Journal of Cell Biology 142(3): 625-633. Malumbres, M. and M. Barbacid (2009). 'Cell cycle, CDKs and cancer: a changing paradigm.' Nat Rev Cancer 9(3): 153-166. Mandal, M., D. J. Olson, T. Sharma, R. K. Vadlamudi and R. Kumar (2001). 'Butyric acid induces apoptosis by up-regulating Bax expression via stimulation of the c-Jun N-terminal kinase/activation protein-1 pathway in human colon cancer cells.' Gastroenterology 120(1): 71-78. Mariadason, J. M. (2008). 'HDACs and HDAC inhibitors in colon cancer.' Epigenetics 3(1): 28-37. Mariadason, J. M., K. L. Rickard, D. H. Barkla, L. H. Augenlicht and P. R. Gibson (2000). 'Divergent phenotypic patterns and commitment to apoptosis of Caco-2 cells during spontaneous and butyrate-induced differentiation.' J Cell Physiol 183(3): 347-354. Matson, D. R. and P. T. Stukenberg (2011). 'Spindle poisons and cell fate: a tale of two pathways.' Mol Interv 11(2): 141-150. McDaid, H. M. and S. B. Horwitz (2001). 'Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines.' Molecular Pharmacology 60(2): 290-301. Minotti, A. M., S. B. Barlow and F. Cabral (1991). 'Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin.' Journal of Biological Chemistry 266(6): 3987-3994. Mischak, H., J. A. Goodnight, W. Kolch, G. Martiny-Baron, C. Schaechtle, M. G. Kazanietz, P. M. Blumberg, J. H. Pierce and J. F. Mushinski (1993). 'Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity.' J Biol Chem 268(9): 6090-6096. Mollinedo, F. and C. Gajate (2003). 'Microtubules, microtubule-interfering agents and apoptosis.' Apoptosis 8(5): 413-450. Nagata, K., A. Puls, C. Futter, P. Aspenstrom, E. Schaefer, T. Nakata, N. Hirokawa and A. Hall (1998). 'The MAP kinase kinase kinase MLK2 co-localizes with activated JNK along microtubules and associates with kinesin superfamily motor KIF3.' EMBO Journal 17(1): 149-158. Nogales, E. (2000). 'Structural insights into microtubule function.' Annual Review of Biochemistry 69: 277-302. Orchel, A., Z. Dzierzewicz, B. Parfiniewicz, L. Weglarz and T. Wilczok (2005). 'Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent.' Dig Dis Sci 50(3): 490-498. Palmer, A., A. C. Gavin and A. R. Nebreda (1998). 'A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1.' EMBO Journal 17(17): 5037-5047. Perletti, G. and D. M. Terrian (2006). 'Distinctive cellular roles for novel protein kinase C isoenzymes.' Curr Pharm Des 12(24): 3117-3133. Perletti, G. P., E. Marras, P. Concari, F. Piccinini and A. H. Tashjian, Jr. (1999). 'PKCdelta acts as a growth and tumor suppressor in rat colonic epithelial cells.' Oncogene 18(5): 1251-1256. Philchenkov, A. (2004). 'Caspases: potential targets for regulating cell death.' J Cell Mol Med 8(4): 432-444. Pines, J. (2011). 'Cubism and the cell cycle: the many faces of the APC/C.' Nat Rev Mol Cell Biol 12(7): 427-438. Rahmouni, S., F. Cerignoli, A. Alonso, T. Tsutji, R. Henkens, C. Zhu, C. Louis-dit-Sully, M. Moutschen, W. Jiang and T. Mustelin (2006). 'Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence.' Nat Cell Biol 8(5): 524-531. Reshetnikova, G., S. Troyanovsky and D. L. Rimm (2007). 'Definition of a direct extracellular interaction between Met and E-cadherin.' Cell Biol Int 31(4): 366-373. Reszka, A. A., J. C. Bulinski, E. G. Krebs and E. H. Fischer (1997). 'Mitogen-activated protein kinase/extracellular signal-regulated kinase 2 regulates cytoskeletal organization and chemotaxis via catalytic and microtubule-specific interactions.' Molecular Biology of the Cell 8(7): 1219-1232. Reszka, A. A., R. Seger, C. D. Diltz, E. G. Krebs and E. H. Fischer (1995). 'Association of mitogen-activated protein kinase with the microtubule cytoskeleton.' Proceedings of the National Academy of Sciences of the United States of America 92(19): 8881-8885. Rieder, C. L. and H. Maiato (2004). 'Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint.' Dev Cell 7(5): 637-651. Roberts, E. C., P. S. Shapiro, T. S. Nahreini, G. Pages, J. Pouyssegur and N. G. Ahn (2002). 'Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosis.' Molecular and Cellular Biology 22(20): 7226-7241. Ropero, S., M. F. Fraga, E. Ballestar, R. Hamelin, H. Yamamoto, M. Boix-Chornet, R. Caballero, M. Alaminos, F. Setien, M. F. Paz, M. Herranz, J. Palacios, D. Arango, T. F. Orntoft, L. A. Aaltonen, S. Schwartz, Jr. and M. Esteller (2006). 'A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.' Nat Genet 38(5): 566-569. Saito, A., T. Yamashita, Y. Mariko, Y. Nosaka, K. Tsuchiya, T. Ando, T. Suzuki, T. Tsuruo and O. Nakanishi (1999). 'A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.' Proc Natl Acad Sci U S A 96(8): 4592-4597. Schmid-Alliana, A., L. Menou, S. Manie, H. Schmid-Antomarchi, M. A. Millet, S. Giuriato, B. Ferrua and B. Rossi (1998). 'Microtubule integrity regulates src-like and extracellular signal-regulated kinase activities in human pro-monocytic cells. Importance for interleukin-1 production.' Journal of Biological Chemistry 273(6): 3394-3400. Schramek, H. (2002). 'MAP kinases: from intracellular signals to physiology and disease.' News Physiol Sci 17: 62-67. Semb, H. and G. Christofori (1998). 'The tumor-suppressor function of E-cadherin.' Am J Hum Genet 63(6): 1588-1593. Sengupta, S., J. G. Muir and P. R. Gibson (2006). 'Does butyrate protect from colorectal cancer?' J Gastroenterol Hepatol 21(1 Pt 2): 209-218. Sengupta, S., J. G. Muir and P. R. Gibson (2006). 'Does butyrate protect from colorectal cancer?' Journal of Gastroenterology and Hepatology 21(1 Pt 2): 209-218. Shapiro, P. S., E. Vaisberg, A. J. Hunt, N. S. Tolwinski, A. M. Whalen, J. R. McIntosh and N. G. Ahn (1998). 'Activation of the MKK/ERK pathway during somatic cell mitosis: direct interactions of active ERK with kinetochores and regulation of the mitotic 3F3/2 phosphoantigen.' Journal of Cell Biology 142(6): 1533-1545. Skoudy, A., M. D. Llosas and A. Garcia de Herreros (1996). 'Intestinal HT-29 cells with dysfunction of E-cadherin show increased pp60src activity and tyrosine phosphorylation of p120-catenin.' Biochem J 317 ( Pt 1): 279-284. Soloaga, A., S. Thomson, G. R. Wiggin, N. Rampersaud, M. H. Dyson, C. A. Hazzalin, L. C. Mahadevan and J. S. Arthur (2003). 'MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14.' EMBO Journal 22(11): 2788-2797. Spurling, C. C., C. A. Godman, E. J. Noonan, T. P. Rasmussen, D. W. Rosenberg and C. Giardina (2008). 'HDAC3 overexpression and colon cancer cell proliferation and differentiation.' Mol Carcinog 47(2): 137-147. Stadheim, T. A., H. Xiao and A. Eastman (2001). 'Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells.' Cancer Research 61(4): 1533-1540. Tanimura, S., A. Uchiyama, K. Watanabe, M. Yasunaga, Y. Inada, T. Kawabata, K. Iwashita, S. Noda, K. Ozaki and M. Kohno (2009). 'Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubule-destabilizing agents in tumor cells.' Biochemical and Biophysical Research Communications 378(3): 650-655. Tsanou, E., D. Peschos, A. Batistatou, A. Charalabopoulos and K. Charalabopoulos (2008). 'The E-cadherin adhesion molecule and colorectal cancer. A global literature approach.' Anticancer Res 28(6A): 3815-3826. Verlhac, M. H., H. de Pennart, B. Maro, M. H. Cobb and H. J. Clarke (1993). 'MAP kinase becomes stably activated at metaphase and is associated with microtubule-organizing centers during meiotic maturation of mouse oocytes.' Developmental Biology 158(2): 330-340. Walsh, S., S. S. Margolis and S. Kornbluth (2003). 'Phosphorylation of the cyclin b1 cytoplasmic retention sequence by mitogen-activated protein kinase and Plx.' Mol Cancer Res 1(4): 280-289. Wang, Q., X. Wang, A. Hernandez, S. Kim and B. M. Evers (2001). 'Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation.' Gastroenterology 120(6): 1381-1392. Wang, R., G. He, M. Nelman-Gonzalez, C. L. Ashorn, G. E. Gallick, P. T. Stukenberg, M. W. Kirschner and J. Kuang (2007). 'Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition.' Cell 128(6): 1119-1132. Wang, T. H., H. S. Wang, H. Ichijo, P. Giannakakou, J. S. Foster, T. Fojo and J. Wimalasena (1998). 'Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways.' Journal of Biological Chemistry 273(9): 4928-4936. Waskiewicz, A. J., J. C. Johnson, B. Penn, M. Mahalingam, S. R. Kimball and J. A. Cooper (1999). 'Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo.' Molecular and Cellular Biology 19(3): 1871-1880. Wilson, A. J., D. S. Byun, N. Popova, L. B. Murray, K. L'Italien, Y. Sowa, D. Arango, A. Velcich, L. H. Augenlicht and J. M. Mariadason (2006). 'Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.' J Biol Chem 281(19): 13548-13558. Witt, O., H. E. Deubzer, T. Milde and I. Oehme (2009). 'HDAC family: What are the cancer relevant targets?' Cancer Lett 277(1): 8-21. Wolpin, B. M. and R. J. Mayer (2008). 'Systemic treatment of colorectal cancer.' Gastroenterology 134(5): 1296-1310. Wright, J. H., E. Munar, D. R. Jameson, P. R. Andreassen, R. L. Margolis, R. Seger and E. G. Krebs (1999). 'Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts.' Proceedings of the National Academy of Sciences of the United States of America 96(20): 11335-11340. Wullschleger, S., R. Loewith and M. N. Hall (2006). 'TOR signaling in growth and metabolism.' Cell 124(3): 471-484. Yan, Y., R. S. Spieker, M. Kim, S. M. Stoeger and K. H. Cowan (2005). 'BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.' Oncogene 24(20): 3285-3296. Zhao, Y., D. He, R. Stern, P. V. Usatyuk, E. W. Spannhake, R. Salgia and V. Natarajan (2007). 'Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.' Cell Signal 19(11): 2329-2338. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57110 | - |
dc.description.abstract | 台灣衛生福利部國民健康署統計資料顯示,惡性腫瘤已居國內十大死因之首近三十多年,其中大腸直腸癌發生率已躍居癌症的第一位;另外,根據世界衛生組織 WHO 公佈的 GLOBOCAN 統計,大腸直腸癌為世界上癌症死因中第三位。相對於其他癌症的發生病因,大腸直腸癌已確立明確的致病機轉:adenoma-carcinoma sequence,乃是一高度具有發生順序性的模式。本實驗室與美國北卡羅來納教堂山分校藥學系李國雄院士及臺北醫學大學藥學系劉景平教授合作,分別探討天然藥物衍生物 DYZ-2-90 和小分子藥物 MPT0G030 在大腸直腸癌中的抗癌機轉。
在腸癌細胞 HT-29 不正常增生的情況下,利用 DYZ-2-90 抑制細胞過度的生長。DYZ-2-90 是修飾自上品中藥丹蔘萃取成分 neo-tanshinlactone 的一個新穎的開環化合物,可直接和微管結合抑制微管的聚合作用,使細胞分裂中重要的紡錘絲去聚合。然而,紡錘絲結構的崩解不僅使細胞週期停滯於 G2/M 期,也使得原本微管上的訊息傳遞分子 ERK 持續活化,用以維持細胞存活的訊號,避免細胞凋亡以進行細胞的自我修復;而在藥物作用的後期,因細胞長期停滯於 G2/M 期,對細胞反而累積成為一股 mitotic stress 刺激 JNK 活化,使受到藥物損傷的細胞經過活化 caspase 走向細胞凋亡。因此在 DYZ-2-90 的作用之下,癌細胞的命運由兩條互相競爭的路徑來決定,可說是 Mitotic exit threshold 與 Death threshold 之間的競爭,也可說是 ERK (細胞生存、細胞週期停滯) 和 JNK (細胞凋亡) 路徑間的競爭。 另一方面,利用 HDAC 抑制劑 MPT0G030 引導腸癌細胞 HT-29 進行正常腸細胞的生命週期,走向細胞分化與細胞凋亡。MPT0G030 是一個有效的抗癌藥物,對許多不同人類癌細胞株都有很好的毒殺作用。不僅可以有效抑制許多腫瘤組織中會過度表現的 class I HDACs,在人類大腸直腸癌細胞中也可活化 PKCδ,促使 E-cadherin 重新分佈、改變細胞形態,使癌細胞分化並走向死亡;並且也證明 HDAC1 會調控 PKCδ 的活化。在 HT-29 人類腫瘤異體移植的抗癌作用模型中,也證實了 MPT0G030 對 HDAC1 和 PKCδ 的作用與細胞實驗結果一致。 綜合以上兩部分的論文結果顯示,DYZ-2-90 是一個有效的去微管抑制劑,而 MPT0G030 是一個有效的 class I HDAC 抑制劑,分別抑制腸癌中失控的細胞生長及促進細胞分化,兩者都俱有發展為人類大腸直腸癌化學治療藥物的潛力。 | zh_TW |
dc.description.abstract | Latest statistics reported by Taiwan’s Health Promotion Administration, malignancy has been the major causes of death in Taiwan for 30 years; among those, colorectal cancer is the first-leading cause of cancer deaths. Meanwhile, colorectal cancer is the 3rd most common cancer worldwide. In contrast to other cancers, development of colorectal cancer is an ordered event of genetic and epigenetic changes that called adenoma-carcinoma sequence. Our laboratory cooperates with Dr. Kuo-Hsiung Lee (Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA) and Dr. Jing-Ping Liou (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan) to evaluate the anticancer effect and the underlying mechanisms of DYZ-2-90 and MPT0G030 in human colorectal cancer, respectively.
In situations of aberrant hyperproliferation, DYZ-2-90 targets to the mitotic spindles, the critical structure of cell mitosis, and leads to microtubule depolymerization in HT-29 cells. DYZ-2-90 is a novel ring-opened compound modified from neo-tanshinlactone isolated from Chinese medicinal herb Tanshen. It binds directly to microtubules and rapidly suppresses microtubule polymerization in human colorectal cancer cells. Thus, the alteration of mitotic spindle organization changes the scaffolding properties of microtubules, which induces strong and sustained ERK activation and leads to mitotic arrest. Prolonged ERK activation and cyclin B degradation contributes to maintain the cell mitotic state and protect cells from apoptosis, but meanwhile provides more time to accumulate mitotic stress/cell death signals. Then, the cell apoptosis is triggered by anti-apoptotic protein Mcl-1 degradation and JNK activation, which breach the death threshold. The cell fate of mitotic arrest cells is dictated by two competing networks: one is the cytoprotective ERK pathway, and the other is stressed-related JNK pathway. Whereas, MPT0G030, a HDAC inhibitor, redirects colorectal cancer cells (HT-29 cells) to normal colonic life cycle to undergo cell differentiation and cell apoptosis. MPT0G030 is a potent HDAC inhibitor that showed broad-spectrum cytotoxicity against various human cancer cell lines. It not only effectively inhibits class I HDACs, which are overexpressed in many malignant neoplasms, but also redistributes E-cadherin and activates PKCδ, which is linked to cell apoptosis and differentiation. Further, activation of PKCδ is demonstrated to be modulated through HDAC1. Collectively, MPT0G030-induced PKCδ participates in cell apoptosis and concomitantly promotes differentiation of colon cancer cells through E-cadherin redistribution and changes in cell morphology. In this thesis, our results indicate that both DYZ-2-90, a novel microtubule-destabilizing agent, and MPT0G030, a class I HDAC inhibitor, have great potential as new drug candidates for colorectal cancer therapy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T06:35:11Z (GMT). No. of bitstreams: 1 ntu-103-F97443010-1.pdf: 12468605 bytes, checksum: ae5ed0d2da111555cfe077a1a8d988eb (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 口試委員會審定書 I
致謝 II 縮寫表 III 中文摘要 IV 英文摘要 VI 第一章 緒論 1 第一節 研究動機與目的 1 第二節 文獻回顧 3 第二章 實驗材料與方法 33 第一節 實驗材料 33 第二節 實驗方法 34 第三章 抗微管藥物 DYZ-2-90 引起細胞凋亡之機轉探討 40 中文摘要 41 英文摘要 42 第一節 實驗結果 43 第二節 討論 49 第四章 HDAC 抑制劑 MPT0G030 引起細胞凋亡及細胞分化之機轉探討 64 中文摘要 65 英文摘要 66 第一節 實驗結果 67 第二節 討論 71 第五章 總結與展望 88 著作 91 參考文獻 93 | |
dc.language.iso | zh-TW | |
dc.title | 探討 DYZ-2-90 和 MPT0G030 在人類大腸直腸癌細胞中之抗癌機轉 | zh_TW |
dc.title | Evaluation of mechanisms underlying anticancer activity of DYZ-2-90 and MPT0G030 in human colorectal cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 顏茂雄(Mao-Hsiung Yen),楊春茂(Chuen-Mao Yang),黃德富(Tur-Fu Huang) | |
dc.subject.keyword | 大腸直腸癌,微管,HDAC,細胞分化,DYZ-2-90,MPT0G030, | zh_TW |
dc.subject.keyword | colorectal cancer,microtubule,HDAC,cell differentiation,DYZ-2-90,MPT0G030, | en |
dc.relation.page | 103 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 12.18 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。